NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tesla, Inc. ("Tesla" or the "Company") (NASDAQ: TSLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. On news of the NHTSA investigation, Tesla's stock price fell sharply, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of c ...

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (NYSE: XIFR).Shareholders who purchased shares of XIFR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/xplr-infrastructure-lp-f-k-a-nextera-energy-partn ...

Core Viewpoint - Jasper Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price due to issues related to a drug product lot in a clinical study [1][2]. Group 1: Company Overview - Jasper Therapeutics, Inc. is publicly traded on NASDAQ under the ticker symbol JSPR [1]. - The company recently reported updated data from its BEACON Phase 1b/2a study of briquilimab, which is intended for adult participants with chronic spontaneous urticaria (CSU) [2]. Group 2: Recent Developments - On July 7, 2025, Jasper announced that results from certain dose cohorts of its clinical study were confounded by issues with a specific drug product lot, affecting 10 out of 13 patients in those cohorts [2]. - Following this announcement, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of Jasper investors, focusing on potential securities fraud and misconduct by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].

Core Viewpoint - Abacus Global Management, Inc. is under investigation for potential securities fraud and unlawful business practices, following allegations of manipulating financial reporting to appear more profitable than it is [1][2]. Group 1: Investigation and Allegations - An investigation is being conducted on behalf of investors of Abacus Global Management regarding possible securities fraud by the company and its officers or directors [1]. - A report by Morpheus Research claims that Abacus has altered its portfolio valuation methodology to inflate profitability and uses questionable life expectancy calculations, raising concerns about the integrity of its financial practices [2]. Group 2: Market Reaction - Following the news of the investigation and the allegations, Abacus's stock price experienced a significant decline, falling by $1.64 per share, or 21.47%, closing at $6.00 per share on June 5, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Brown-Forman Corporation and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][2]. Financial Performance - Brown-Forman reported a 7.3% year-over-year decline in sales for fiscal year 2025, with earnings per share of $0.31, which fell short of consensus estimates [2]. - The company acknowledged that its results did not meet long-term growth aspirations and indicated expectations of continued headwinds for fiscal 2026 [2]. Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation on behalf of investors who may have been affected by Brown-Forman's alleged misconduct [1][3].

Core Viewpoint - A class action securities lawsuit has been filed against DoubleVerify Holdings, Inc. alleging securities fraud affecting investors between November 10, 2023, and February 27, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DoubleVerify's customers are shifting ad spending from open exchanges to closed platforms, limiting the company's technological capabilities and increasing competition from platforms like Meta and Amazon [2] - It is alleged that DoubleVerify's ability to monetize its Activation Services is constrained due to the high costs and time required for technology development for closed platforms [2] - The complaint states that monetization of DoubleVerify's Activation Services on certain closed platforms could take several years [2] - Competitors are reportedly better positioned to integrate AI into their offerings on closed platforms, negatively impacting DoubleVerify's competitive edge and profitability [2] - The company is accused of systematically overbilling customers for ad impressions served to declared bots from known data center server farms [2] - The risk disclosures provided by DoubleVerify are claimed to be materially false and misleading, presenting adverse facts as mere possibilities [2] - As a result of these issues, the lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially false or lacked a reasonable basis [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DoubleVerify Holdings, Inc. during the specified timeframe have until July 21, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for allegedly making false and misleading statements regarding its financial stability and restructuring plan during the Class Period from January 29, 2024, to March 11, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone company [5]. - It is alleged that the defendants' public statements were materially false and misleading, which resulted in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen Inc. made materially false and misleading statements regarding PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the product's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Group 1 - Centene Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - On July 1, 2025, Centene withdrew its 2025 GAAP and adjusted diluted earnings per share guidance due to underperformance in market growth across 22 out of 29 states and higher-than-expected health risks affecting revenue calculations [2] - Following the announcement, Centene's stock price dropped by $22.87, or 40.37%, closing at $33.78 per share on July 2, 2025 [3] Group 2 - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]